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Abstract
Alterations of receptor-type tyrosine kinases (RTK) are frequent in human cancers. They can result
from translocation, mutation or amplification. The ERBB2 RTK is encoded by a gene that is
amplified in about 20% breast cancers. The question is: why is this RTK specifically subjected to this
type of alteration? We propose that ERBB2 gene amplification is used to overcome repression of
its expression by sequence-specific transcription factors.
Background
Receptor-type tyrosine kinases (RTK) are major regulators
of cellular processes. As such they are often mutated in
human cancers. Several types of alterations have been
characterized. Translocations, amplifications and muta-
tions affect many RTK genes in various types of tumors.
One of the earliest reports of RTK alteration in human
cancer was issued more than twenty years ago. It described
the amplification of the ERBB2 RTK gene in a good pro-
portion of breast cancers [1]. This initial discovery
launched the search for other RTK alterations in human
tumors. This still ongoing search has registered a recent
success in neuroblastoma. The ALK RTK gene, which is
translocated and fused to various partner genes in lym-
phomas and non-small cell lung cancer [2], has been
found amplified and mutated in neuroblastoma [3-6].
While there is no doubt that RTK alterations are central to
many malignant diseases such as thyroid, lung and breast
cancers, a major question remains: what determines the
mechanism of alteration (fusion, amplification or muta-
tion) of an RTK oncogene?
Hypothesis
Translocation with fusion may be necessary to both acti-
vate the tyrosine kinase and express the oncogenic
enzyme in a given tissue or cell. The partner gene will pro-
vide the appropriate promoter, dimerization motifs and
protein subcellular localization. Mutation is an obvious
way of constitutive activation of a kinase. Amplification of
the mutated gene, as observed for ALK in neuroblastoma,
enhances this effect. But why are some RTK genes such as
ERBB2 amplified without mutation or rearrangement? We
would like to propose an explanation.
A series of recent works has shed new light on the regula-
tion of ERBB2 in mammary epithelial cells. Expression of
this gene is apparently tightly controled by a number of
transcriptional repressors. FOXP3 represses ERBB2 expres-
sion, and acts as a tumor suppressor when inactivated [7].
Similarly, PAX2 mediates estrogen receptor (ER) induced
repression of ERBB2 [8]. We recently found that GATA4 is
also a repressor of ERBB2 expression [9]. The ETS family
member PEA3 can also act as an ERBB2 inhibitor [10].
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The Y-box transcription factor CSDA/ZONAB represses
ERBB2 in a cell-density-dependent manner [11]. Finally, it
has been known for long that MYB, which is expressed in
ER-positive cells, represses ERBB2 [11]. Thus, at least six
transcription factors acting as transcriptional repressors of
the ERBB2 gene have been described so far. It remains to
determine whether some, if not all, of these sequence-spe-
cific DNA-binding proteins share a common cofactor such
as the CTBP corepressor [12], and how many such repres-
sors control the ERBB2 promoter.
The central role of ERBB2 in mammary gland biology
makes it a frequent target of mammary oncogenesis. The
ERBB2 protein is active in some types of mammary epi-
thelial cells at given periods of development and differen-
tiation but it must be low or absent in ER-positive
differentiated cells. The progenitors of these cells should
not proliferate outside these regulated periods of mam-
mary gland activity. In these cells ERBB2  by-default
expression is quenched by strong repressors. We hypothe-
size that amplification of the ERBB2 gene and its cognate
non-coding regulatory sequences titrates out these repres-
sors, uncovering a permanent proliferative effect of the
ectopically-expressed ERBB2 protein in the progenitors of
ER-positive cells. ERBB2 overexpression could in turn shut
down more or less tightly ER expression (Figure 1),
Schematic representation of the repression/amplification model in mammary epithelial cells Figure 1
Schematic representation of the repression/amplification model in mammary epithelial cells. In these cells 
ERBB2 expression is regulated. A crosstalk between ER and ERBB2 pathways is an important feature of these cells. ERBB2 is 
normally expressed at low level in ER-negative cells (A). In ER-positive cells, ERBB2 expression is quenched by ER-induced tran-
scriptional repressors (B). In ERBB2-positive tumors, amplification titrates out the repressors and allows overexpression of 
ERBB2; this may in turn shut down ER expression (C).
ERBB2
ER+, ERBB2-
MYB
PAX2
FOXP3
ERBB2
ERBB2
ERBB2
MYB
PAX2
FOXP3
ERBB2+, ER-
ER
ERBB2
ERBB2
ERBB2
MYB
PAX2
FOXP3
ERBB2+, ER+
ER
ERBB2
ER-
AB
CCancer Cell International 2009, 9:5 http://www.cancerci.com/content/9/1/5
Page 3 of 4
(page number not for citation purposes)
through the MTA1 repressor [13], the NFKB pathway [14]
or other means. When ocurring in ER-negative progeni-
tors, amplification of ERBB2 could overcome other repres-
sors that just maintain the necessary low level of
expression of ERBB2 mRNA, hence increasing the amount
of receptor protein up to pathological level.
Other ERBB2 repressors remain probably to be discov-
ered, possibly within the list of numerous transcription
factors specifically expressed in ER-positive cells [15].
Because of these many and strong repressors, an ERBB2
mutated gene would still be repressed and a cell carrying
an  ERBB2  mutation could not be selected. Thus, gene
mutation would not be an efficient way to activate ERBB2.
Testing the hypothesis
Previous works [7] have provided so solid a ground to the
hypothesis that it may almost be considered proven. They
have shown that overexpression of repressors suppress
ERBB2 mRNA expression in ERBB2-amplified cells. Sys-
tematic test of many candidate repressors could be done.
There are a number of other relatively easy experiments
that would further validate the hypothesis, such as testing
if increased expression of ERBB2 promoter sequences in
mammary epithelial cells, mimicking amplification,
would titrate out repressors.
Close examination of the genome of ERBB2 tumors will
give us much information. Loss of function of a repressor
locus (or several cooperative loci) by deletion or mutation
may lead to de novo ERBB2 expression and synergize with
amplification. FOXP3 mutations have indeed been
observed in breast cancer cells [7]. One can also imagine
that mutations in the ERBB2 promoter region that would
remove a repressor binding site may have an effect on
ERBB2  expression. A good proportion of tumors that
overexpress ERBB2 do not display ERBB2 gene amplifica-
tion; these tumors could have such loss or mutation. The
sequencing of whole tumor genomes will soon tell us if
this is the case.
More general implications
RTK  genes can display different oncogenic alterations.
Titration of sequence-specific repressors or corepressors
could be the mechanism at stake in other cases of RTK
amplification. It could also take place in cases of non-RTK
gene amplification without mutation. However, in many
of these cases (e.g. cyclin D1 or cyclin E in breast cancers),
amplification may be the alteration of choice simply
because the oncogenic product is the overexpressed nor-
mal protein and mutation will not do. Acquisition of a
new promoter by translocation and gene fusion would
also free an RTK oncogene from its natural repressors but
has different effects from amplification; it could modify
signaling pathways and/or target different cells; in addi-
tion constitutive dimerization and activation could
bypass other regulatory controls.
In the same line of reasoning, accumulation of gene cop-
ies could be a mechanism to escape negative control by
microRNAs or any other type of inhibition. For example,
amplification might also titrate out methylases to turn on
the ERBB2 promoter.
The biology of transcriptional repressors will have clinical
use. First, knowledge of repressor status may help progno-
sis assessment and selection of patients for appropriate
treatment [8]. Second, transcription could be tightly
linked to the development of new therapies. The control
of ERBB2 gene expression by specific drugs could syner-
gize with anti-receptor or anti-kinase therapy. It should
aim at restoring ERBB2 repression or inhibiting ERBB2
transcription [16,17]. Preclinical trials have used with suc-
cess expression of PEA3 on mouse xenografts [10]. Chi-
meric ETS proteins have also shown ERBB2
downregulating activity in cell lines [18]. A clinical trial
using intratumoral delivery of adenovirus E1A, which can
also repress ERBB2  expression, has been launched in
breast cancer [19]. Members of the FOX family of tran-
scription factors, some of which interact both with ERBB2
and ER, are emerging as promising therapeutic targets
[20]. Large-scale screens of natural or chemical drugs that
modulate  ERBB2  expression and its interplay with ER
could yield interesting molecules [21,22]. A better knowl-
edge of ERBB2 promoter and associated transcription fac-
tors will probably help find new targets and design new
strategies.
The mechanism of oncogenesis involving an RTK may
give a clue as to what kind of cell is targeted. A mutated
RTK may trigger oncogenic transformation in a cell where
it is normally expressed, using the same signaling pathway
but in a permanent fashion. An amplified RTK could trig-
ger oncogenesis in a cell (in the case of ERBB2 it could be
an ER-positive progenitor cell) where it is normally
repressed if the reason for the amplification is to remove
transcriptional repression, or in a cell where it is normally
expressed if the reason is to rise the level of protein made.
Amplification of other RTK genes such as EGFR, FGFR1,
FGFR2 and IGF1R occurs in various subtypes of breast
cancers [23]. It will be interesting to determine whether
these genes are also under transcriptional repression and
if a general mechanism of oncogenesis associates loss of
transcription repressors acting as tumor suppressors and
gain of signaling molecules acting as oncogenes.
ERBB2 is associated with stem cell biology in the mam-
mary gland and breast cancer [24]. It would be interesting
to determine the level of repressors in breast stem cellsPublish with BioMed Central    and   every 
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and progenitors. Modulation of these repressors may play
a role in self-renewal and differentiation.
Finally, the titration of ERBB2 repressors by ERBB2 pro-
moter amplification may free other genes from repression
by the same transcription factors. ERBB2 amplification
would thus have consequences outside the activated sign-
aling pathway of the receptor itself. Some of these "liber-
ated" genes might be found upregulated in gene
expression analyses of ERBB2-amplified tumors [25]. This
may explains at least in part why ERBB2 amplification is
associated with a bona fide breast cancer subtype.
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